A new collaboration between Trinity Biotech and University at Buffalo will advance the commercialization of novel biomarkers for earlier and more accurate detection of Sjögren’s Syndrome—highlighting the critical role of UB’s research ecosystem and industry partnerships in translating innovation to market.
The agreement centers on proprietary biomarkers discovered by UB faculty and licensed through UB Business and Entrepreneur Partnerships (BEP). Through BEP’s Technology Transfer Office, UB’s intellectual property is being advanced into commercial diagnostic applications, with Trinity Biotech co-developing and bringing these assays to market via its U.S.-based reference laboratory.
UB’s contribution is rooted in both scientific discovery and sustained translational support. The underlying research was funded in part by BEP’s Center for Advanced Technology in Big Data and Health Sciences (UB CAT), which provides milestone-driven, applied R&D funding to accelerate industry collaboration and commercialization. This multi-year funding model helps bridge early-stage innovation to market-ready technologies.
Read the full story .